{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:09Z","timestamp":1792786149048,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81500431"],"award-info":[{"award-number":["81500431"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770561"],"award-info":[{"award-number":["81770561"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970499"],"award-info":[{"award-number":["81970499"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970499"],"award-info":[{"award-number":["81970499"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20151039"],"award-info":[{"award-number":["BK20151039"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010014","name":"Six Talent Peaks Project in Jiangsu Province","doi-asserted-by":"crossref","award":["2018-WSW-003"],"award-info":[{"award-number":["2018-WSW-003"]}],"id":[{"id":"10.13039\/501100010014","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangsu Province Leading Talents and Innovation Team","award":["CXTDA2017033"],"award-info":[{"award-number":["CXTDA2017033"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>\n                      Antibiotic resistance poses a challenge for\n                      <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                      eradication treatment. Current guidelines strongly recommend avoiding repeated treatments with the same antibiotic to prevent the emergence of drug resistance. However, for penicillin-allergic patients with recurrent\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication failures, avoiding repeated treatments with the same antibiotic severely limits the choice of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 47-year-old woman with a penicillin allergy for whom 2 previous levofloxacin and bismuth-based therapies had failed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Agar dilution susceptibility testing and gene sequence analysis was performed to confirm levofloxacin susceptibility again. Therefore, we treated her with a 14-day regimen consisting of levofloxacin (500\u200amg once daily), furazolidone (100\u200amg twice daily), colloidal bismuth pectin (220\u200amg twice daily), and esomeprazole (20\u200amg twice daily).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient was successfully treated with a third levofloxacin and bismuth-based regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Antibiotics included in previous failed therapies need not be eliminated if no antibiotic resistance is found on antimicrobial susceptibility testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000024915","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T20:02:49Z","timestamp":1615492969000},"page":"e24915","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection"],"prefix":"10.1097","volume":"100","author":[{"given":"Siya","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University"},{"name":"First Clinical Medical College of Nanjing Medical University, Nanjing, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University"},{"name":"First Clinical Medical College of Nanjing Medical University, Nanjing, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duochen","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University"},{"name":"First Clinical Medical College of Nanjing Medical University, Nanjing, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University"},{"name":"First Clinical Medical College of Nanjing Medical University, Nanjing, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-1817","authenticated-orcid":false,"given":"Feng","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University"},{"name":"First Clinical Medical College of Nanjing Medical University, Nanjing, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/00365521.2017.1413132","article-title":"Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study","volume":"53","author":"Li","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"e02530-16","DOI":"10.1128\/AAC.02530-16","article-title":"Phenotypic and molecular antimicrobial susceptibility of Helicobacter pylori","volume":"61","author":"Chen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12889-019-6804-3","article-title":"Fluoroquinolone consumption and Escherichia coli resistance in Japan: an ecological study","volume":"19","author":"Terahara","year":"2019","journal-title":"BMC Public Health"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.3748\/wjg.v21.i21.6698","article-title":"Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy","volume":"21","author":"Paoluzi","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4166\/kjg.2012.59.6.401","article-title":"Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori","volume":"59","author":"Jeong","year":"2012","journal-title":"Korean J Gastroenterol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/MEG.0000000000000960","article-title":"Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection","volume":"29","author":"Costa","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11684-019-0706-8","article-title":"Is tailored therapy based on antibiotic susceptibility effective ? A multicenter, open-label, randomized trial","volume":"14","author":"Pan","year":"2020","journal-title":"Front Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apm.12896","article-title":"Replicon typing of plasmids in environmental Achromobacter sp. producing quinolone-resistant determinants","volume":"126","author":"Furlan","year":"2018","journal-title":"APMIS"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijmm.2013.02.001","article-title":"Plasmids and the spread of resistance","volume":"303","author":"Carattoli","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.45.3.727-733.2001","article-title":"Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori","volume":"45","author":"Wang","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/IDR.S235615","article-title":"Mutations in the antibiotic target genes related to clarithromycin, metronidazole and levofloxacin resistance in Helicobacter pylori strains from children in China","volume":"13","author":"Zhang","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1523-5378.2006.00415.x","article-title":"Primary levofloxacin resistance and gyrA\/B mutations among Helicobacter pylori in Japan","volume":"11","author":"Miyachi","year":"2006","journal-title":"Helicobacter"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12866-016-0873-6","article-title":"Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal","volume":"16","author":"Miftahussurur","year":"2016","journal-title":"BMC Microbiol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1086\/510074","article-title":"The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection","volume":"44","author":"Carothers","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkw164","article-title":"Pharmacokinetic\/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB","volume":"71","author":"Ghimire","year":"2016","journal-title":"J Antimicrob Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:03:49Z","timestamp":1746324229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024915"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024915","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"2020-12-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}